WO2011104215A1 - Siliciumhaltiges, biologisch degradierbares material zur pro-angiogenetischen therapie - Google Patents
Siliciumhaltiges, biologisch degradierbares material zur pro-angiogenetischen therapie Download PDFInfo
- Publication number
- WO2011104215A1 WO2011104215A1 PCT/EP2011/052561 EP2011052561W WO2011104215A1 WO 2011104215 A1 WO2011104215 A1 WO 2011104215A1 EP 2011052561 W EP2011052561 W EP 2011052561W WO 2011104215 A1 WO2011104215 A1 WO 2011104215A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diseases
- disease
- silicon
- angiogenesis
- biodegradable material
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/04—Polysiloxanes
- C08G77/14—Polysiloxanes containing silicon bound to oxygen-containing groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/62227—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products obtaining fibres
- C04B35/62231—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products obtaining fibres based on oxide ceramics
- C04B35/6224—Fibres based on silica
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/624—Sol-gel processing
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/62605—Treating the starting powders individually or as mixtures
- C04B35/62625—Wet mixtures
- C04B35/6263—Wet mixtures characterised by their solids loadings, i.e. the percentage of solids
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/62605—Treating the starting powders individually or as mixtures
- C04B35/62625—Wet mixtures
- C04B35/62635—Mixing details
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/62605—Treating the starting powders individually or as mixtures
- C04B35/62685—Treating the starting powders individually or as mixtures characterised by the order of addition of constituents or additives
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/30—Constituents and secondary phases not being of a fibrous nature
- C04B2235/44—Metal salt constituents or additives chosen for the nature of the anions, e.g. hydrides or acetylacetonate
- C04B2235/441—Alkoxides, e.g. methoxide, tert-butoxide
Definitions
- Silicon-containing, biodegradable material for pro-angiogenic therapy Silicon-containing, biodegradable material for pro-angiogenic therapy
- the present invention relates to a silicon-containing, biodegradable material for the prophylaxis and / or treatment of diseases associated with diminished and / or impaired angiogenesis and / or diseases for which an increased rate of angiogenesis is conducive to the healing process.
- Angiogenesis refers to the growth of small blood vessels (capillaries), predominantly by budding from a preformed capillary system. It is a complex process in which the endothelial cells, pericytes and smooth muscle cells required to form the vessel walls are activated by various angiogenic growth factors such as Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF).
- FGF Fibroblast Growth Factor
- VEGF Vascular Endothelial Growth Factor
- Pro-angiogenic protein therapy uses growth factors with angiogenic potency, most notably Fibroblast Growth Factor 1 (FGF-1) and Vascular Endothelial Growth Factor (VEGF); With these growth factors, the greatest clinical experience is available. But also the growth factors epidermal growth factor (EGF), platelet-derived endothelial cell growth factor (PD-ECGF) and platelet-derived growth factor (PDGF) and transforming growth factor (TGF) possess a certain angiogenic potency.
- EGF-1 epidermal growth factor
- PD-ECGF platelet-derived endothelial cell growth factor
- PDGF platelet-derived growth factor
- TGF transforming growth factor
- Silicon is a trace element that is important for humans in bonded silicate form. Silicon is a building block of those proteins that are responsible for the strength and elasticity of the tissues. It is also incorporated in connective tissue, bones, skin, hair, nails and blood vessels. In addition, silicon strengthens the immune system of the body, the so-called immune system, and promotes wound healing. Deficiency in silicon results in stunted growth, loss of bone stability with increased risk of osteoporosis, premature hair loss, brittle nails, and skin changes. Possible changes of the skin are increased wrinkling, dryness, scaling, increased horn formation, itching, thickening and painful, slit-shaped tears of the skin due to reduced elasticity.
- US2006 / 0178268A1 describes an aqueous solution consisting of non-colloidal silica and boric acid for the treatment of bone, cartilage, skin, arteries, connective tissue, joint, hair, nail, skin diseases and osteoporosis, rheumatic diseases, arteriosclerosis , Arthritis, cardiovascular diseases, allergic diseases and degenerative diseases.
- US2006 / 0099276A1 discloses a method for producing a silicic acid derivative by hydrolysis of a silicone compound to oligomers in the co-presence of a quaternary ammonium compound, an amino acid or an amino acid source or combinations thereof.
- the silica extrudate can be used as pharmaceuticals for the treatment of infections, nails, hair, skin, tooth, collagen, connective tissue, bone diseases, osteopenia, cell formation for degenerative (aging) processes.
- US6,335,457B 1 discloses a solid wherein silica is complexed with a polypeptide. This patent also discloses therapeutically useful mixtures containing this solid.
- WO2009 / 018356A1 relates to a mixture comprising a sodium phosphate compound, an ammonium compound and a silicate for the prophylaxis or treatment of diseases such as prostate cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, neuronal cancer, bone cancer, HIV syndrome, rheumatoid arthritis, multiple sclerosis, Epstein Barr virus, fibromyalgia, chronic fatigue syndrome, diabetes, Bechets syndrome, irritable bowel syndrome, Crohn's disease, bedsores, trophic ulcers, radiation- or chemotherapy-weakened immune systems, hematomas or combinations thereof.
- diseases such as prostate cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, neuronal cancer, bone cancer, HIV syndrome, rheumatoid arthritis, multiple sclerosis, Epstein Barr virus, fibromyalgia, chronic fatigue syndrome, diabetes, Bechets syndrome, irritable bowel syndrome, Crohn's disease, bedsores, trophic ulcers,
- WO2009 / 052090A2 describes a method for the treatment of inflammatory diseases, autoimmune diseases, bacterial or viral infections and cancer by using a composition containing silicate.
- US2003 / 0018011A1 relates to a pharmaceutical composition comprising a fatty acid and a water-soluble silicate polymer as anti-allergic or anti-inflammatory agent.
- No. 5,534,509 relates to a pharmaceutical composition
- a pharmaceutical composition comprising a water-soluble silicate polymer as the active agent with a saccharide or sugar alcohol as the inert carrier substance for the treatment of allergies, inflammation, pain or for the improvement of peripheral blood circulation or paraesthesia.
- DE19609551C1 describes the production of bioabsorbable (continuous) fibers based on polyhydroxysilicic acid ethyl ester.
- the fibers are used as reinforcing fibers for biodegradable and / or bioabsorbable (implant) materials.
- the fibers can also be used for the production of biodegradable composite materials.
- WO01 / 42428A1 describes a method for the production of a skin implant in which skin cells are applied to the surface of a nutrient solution and these are grown using a surface element consisting of the fibers described in DE19609551C1.
- EP1262542A2 relates to a process for the production of cells, tissues and organs, wherein a fiber matrix is used as cell support substance and / or lead structure according to DE19609551 C1.
- WO2006 / 069567A2 relates to a multilayer dressing in which a fiber matrix according to DE19609551C1 is also used in one layer.
- the multi-layer dressing can be used for the treatment of wound defects such as chronic diabetic-neuropathic ulcers, leg ulcers, bedsores, secondary healing infected wounds, non-irritating, primary healing wounds such as, in particular, ablative lacerations or abrasions.
- WO2008 / 086970A1, WO2008148384A1, PCT / EP2008 / 010412 and PCT / EP2009 / 004806 describe inter alia the preparation of further polyhydroxy-silicic acid ethyl ester compounds which can be used according to the invention.
- the compounds are generally described for use as bioabsorbable materials in human medicine, medical technology, filter technology, biotechnology or the insulation industry. It is also mentioned that the materials can be advantageously used in the field of wound treatment and wound healing.
- Fibers can be used, for example, as surgical sutures or as reinforcing fibers.
- Nonwovens can be superficial in the supply Wounds, in filtration of body fluids (eg blood) or in the bioreactors used as Anzuchthoff.
- biodegradable polyhydroxy-silicic acid ethyl ester compounds eg in the form of a fiber or a nonwoven
- the above-mentioned biodegradable polyhydroxy-silicic acid ethyl ester compounds are used for the prophylaxis and / or treatment of diseases associated with a diminished and / or impaired angiogenesis and / or diseases for which an increased rate of angiogenesis is conducive to the healing process.
- the present invention therefore relates to a silicon-containing, biodegradable material for the prophylaxis and / or treatment of diseases associated with a diminished and / or impaired angiogenesis and / or diseases for which an increased rate of angiogenesis is conducive to the healing process
- the silicon-containing , biodegradable material is a polyhydroxysilicic acid ethyl ester compound, with the proviso that the wound defects, such as chronic diabetic neuropathic ulcer, ulcus cruris, decubitus wounds, secondary healing infected wounds, irritating, primarily healing wounds, such as ablative lacerations or abrasions are excluded.
- the invention also encompasses the use of a silicon-containing, biodegradable polyhydroxysilicic acid ethyl ester compound according to the invention for the preparation of a medicament for the prophylaxis and / or treatment of diseases associated with diminished and / or impaired angiogenesis and / or diseases for the an increased rate of angiogenesis is conducive to the healing process, with the proviso that the wound defects, such as chronic diabetic neuropathic ulcer, ulcus cruris, bedsores wounds, secondarily healing infected wounds, irritating, primarily healing wounds, such as in particular ablative lacerations or abrasions are excluded.
- the wound defects such as chronic diabetic neuropathic ulcer, ulcus cruris, bedsores wounds, secondarily healing infected wounds, irritating, primarily healing wounds, such as in particular ablative lacerations or abrasions are excluded.
- WO2006 / 069567A2 for the treatment of wound defects such as chronic diabetic-neuropathic ulcer, leg ulcers, bedsores wounds, secondarily healing infected wounds, non-irritating, primarily healing wounds, in particular ablative lacerations or abrasions Service.
- EP1262542A2 describes a wide variety of tissue engineering applications of polyhydroxysilicic acid ethyl ester compounds according to the invention.
- tissue engineering applications is based on the products, processes and applications described in EP1262542A2, except for the tissue engineering applications of the silicon-containing and biodegradable material according to the invention, if these are discussed in EP1262542A2 be associated with a pro-angiogenic therapy.
- Polyhydroxykieselkladreethylester- compound refers to compounds of the general formula H [OSi 8 0i 2 (OH) x (OC 2 H 5) 6-x] n OH, wherein x is 2 to 5 and n> 1 ( Polymer).
- inventive silicon-containing, biodegradable material is preferably present as a material in the form of a fiber, a fiber matrix, as a powder, as a monolith and / or as a coating.
- Such a silicon-containing, biodegradable material can be prepared according to the invention as described below:
- the silicon-containing, biodegradable material of the invention preferably exists as fiber, fiber matrix (fleece), as powder, as liquid formulation and / or as coating.
- the subject silicon-containing, biodegradable material is prepared as described above, wherein the tetraethoxysilane in step a) at an initial pH of 0 to ⁇ 7, optionally in the presence of a water-soluble solvent, preferably ethanol, in a Temperature is acid catalysed from 0 ° C to 80 ° C and in step b) evaporating to a single-phase solution having a viscosity in the range of 0.5 to 2 Pa ⁇ s at a shear rate of 10 s "1 at 4 ° C. is carried out.
- the silicon-containing, biodegradable material is prepared as described above, wherein the acid catalysis in step a) with nitric acid H 2 0 in a molar ratio to Si compound in the range 1: 1, 7 to 1: 1 9, preferably in the range of 1: 1, 7 to 1: 1.8.
- the hydrolysis-condensation reaction in step a) is preferably carried out at a temperature of 20 to 60 ° C, preferably 20 to 50 ° C over a period of at least one hour.
- the hydrolysis-condensation reaction proceeds in step a) over a period of several hours, such as 8 hours or 16 hours. However, this reaction can also be carried out over a period of 4 weeks.
- Step (b) is preferred in a preferred embodiment of the invention in a closed apparatus in which mixing is possible (preferably rotary evaporator or stirred tank) with simultaneous removal of the solvent (water, ethanol) by evaporation at a pressure of 1 to 1013 mbar at a pressure of ⁇ 600 mbar, optionally with continuous feed of a chemically inert towing gas for partial pressure reduction of the evaporating components of 1 - 8 m 3 / h (preferably at 2.5 to 4.5 m 3 / h), a reaction temperature of 30 ° C to 90 ° C, preferably 60 to 75 ° C, more preferably at 60 to 70 ° C and preferably with gentle mixing of the reaction system to 80U / min (preferably at 20U / min to 80U / min) up to a viscosity of the mixture 0.5 to 30 Pa ⁇ s at a shear rate of 10 s -1 at 4 ° C., preferably 0.5 to 2 Pa ⁇ s at a shear rate of
- the silicon-containing, biodegradable material in step c) to preferably 2 ° C to 4 ° C, cooled.
- the maturing preferably takes place (step d). Maturation may take several hours or days to about 3 to 4 weeks.
- the ripening process in step d) is preferably carried out up to a viscosity of the sol of 30 to 100 Pa ⁇ s at a shear rate of 10 s -1 at 4 ° C. and a loss factor of 2 to 5 (at 4 ° C., 10 1 / s , 1% deformation).
- the drawing of threads from the silica sol material in step e) is preferably carried out via a spinning process.
- Such a spinning process step can be carried out under customary conditions, as described, for example, in DE 196 09 551 C1 and DE 10 2004 063 599 A1.
- the pressure during the spinning of the silica sol material is selected so that a throughput of at least 80 g / h based on the total sol throughput is achieved.
- the spun fibers are exposed directly after spinning for a period of 30 to 60 minutes to the same climatic conditions as in the spinning tower (i.e., e.g., -19% air humidity, ⁇ 25 ° C temperature).
- This step is referred to below as conditioning.
- the fibers obtained by this process are called conditioned fibers.
- the conditioned fibers are exposed to a relative humidity of at least 35% (at room temperature) for a period of 1 to 30 minutes and preferably a period of 1 to 10 minutes prior to use (see also Table 2).
- the drying of the silica sol material to generate powder is preferably carried out by spray or freeze drying.
- a powder can also be obtained by comminuting and grinding monoliths or else fibers according to the invention.
- the powder is dissolved in a solvent. Suitable solvents may be aqueous or oily depending on the application (e.g., injection solution or suspensions).
- the coating of a material to be coated with the silicon-containing, biodegradable material with the silica sol material is preferably carried out by immersing the body to be coated in the silica sol, by casting or by spin coating or spraying the silica sol.
- the silica sol material according to step d) can also - in order to generate a monolith - be poured into a mold and then dried.
- biodegradable refers to degrading the property of the polyhydroxy-silicic acid ethyl ester compound of the present invention when the material is exposed to conditions typical of those present in a tissue regeneration (e.g., a wound) degradable or biodegradable in the invention is in particular the polyhydroxy-silicic acid ethyl ester compound according to the invention if, after 48 hours, preferably 36 hours and more preferably after 24 hours, in a 0.05 M Tris pH 7.4 buffer solution ( Fluka 93371) thermostatically dissolved at 37 ° C.
- diseases associated with diminished and / or impaired angiogenesis and / or diseases for which an increased rate of angiogenesis promotes the healing process describes all those diseases that can be treated (or prevented) by pro-angiogenic therapy.
- diseases include:
- Bone cartilage or muscle-associated diseases such as:
- Bone / cartilage repair bone defect, bone fracture, bone growth, cartilage disease, bank disc degeneration, osteoarthritis, osteoporosis, spinal fracture, fibromyalgia, polymyositis,
- Central nervous system or peripheral nervous system ischemia Alzheimer's, amyotrophic lateral sclerosis, autonomic neuropathy, aneurysms, cerebral infarction, stroke, cerebrovascular disease, cerebrovascular deficiency, dementia, epilepsy, ischemic peripheral neuropathy, mild cognitive deficits, multiple sclerosis, Nerve damage, Parkinson's disease, Niemann-Pick disease, polyneuropathy,
- d) diseases of the eye such as:
- gastro-intestinal diseases such as:
- Hormonal or metabolic diseases such as:
- Diabetes mellitus, diabetic foot, peripheral diabetic vascular disease
- g) diseases of the immune system such as:
- kidney diseases like:
- Nephropathy intracranial hypertension, renal ischemia
- oral diseases such as:
- k diseases of the reproductive system such as:
- Respiratory diseases such as:
- Asthma, bronchopulmonary dysplasia, pneumonia, respiratory distress syndrome, m) disorders of the skin such as:
- Nonspecific dermatitis decubitus ulcers, dermal ischemia, dermal ulcers, diabetic gangrene, diabetic skin ulcers, lacerations, psoriasis, scleroderma, skin lesions, burns, surgical wounds, wound healing
- Vascular diseases such as:
- Vascular insufficiency vascular restenosis, vasculitis, vascular spasm, Wegener's granulomatosis
- Diseases associated with diminished and / or impaired angiogenesis and / or diseases for which an increased rate of angiogenesis promotes the healing process in a preferred embodiment describes diseases selected from the following group:
- Ischemia in particular of the heart muscle
- Ischemia in the central nervous system or in the peripheral nervous system Ischemia in the central nervous system or in the peripheral nervous system.
- An object of the invention also relates to the use of inventive (r) silicon-containing, biodegradable materials with auto-transplants for the treatment of diseases which are treated by autografts of tissues and / or organs.
- a silicon-containing, biodegradable material according to the invention is used in addition to the autograft in order to achieve an improved angiogenesis and thus a faster incorporation and a better acceptance of the autologous transplant into the existing tissue.
- a further preferred subject matter of the invention relates as silicon-containing, biodegradable material to a polyhydroxysilicic acid ethyl ester compound having an ethoxy group content of at least 20%, preferably of at least 25% and more preferably of 25 to 30%.
- a polyhydroxysilicic acid ethyl ester compound having such an ethoxy group content is in the form of a fiber or a fiber matrix.
- the ethoxy group content is measured by the known standard Zeisel ether cleavage method after spinning within a period of 1 to 4 weeks after spinning, the polyhydroxysilicic acid ethyl ester compound being reduced in humidity (ie, for example, within a package of absorbents such as in European Patent Application EP09007271).
- a further preferred subject matter of the invention relates to a polyhydroxysilicic acid ethyl ester compound in the form of a fiber or a fiber matrix in which the fiber or the fiber matrix has a compressibility of at least 17%, preferably 20% and particularly preferably at least 25%, as the silicon-containing, biodegradable material ,
- the compressibility is measured by the following method steps:
- the compressibility is measured within a period of one week after spinning, with the polyhydroxy-silicic acid ethyl ester compound being stored at reduced humidity (i.e., within an absorbent package, for example) during the time before the measurement.
- the appropriate dosage of the polyhydroxy silicic acid ethyl ester compound is generally between 0.001 to 100 mg / kg body weight per day and administered in single or multiple doses. Preferably, a dosage between 0.01 and 25 mg / kg, more preferably 0.1 to 5 mg / kg per day is used.
- the biodegradable properties of the polyhydroxy-silicic acid ethyl ester compounds also make it possible to apply the compounds in higher dosages and, for example, subcutaneously degrade them within the body as depots in the form of a monolith over a longer period of time and promote pro-angiogenic processes.
- the material according to the invention or a precursor thereof can be processed with the commonly used in galenics carriers, fillers, Zerfallbeeinmannern, binders, lubricants, absorbents, diluents, veryskorrigentien, colorants, etc. and converted into the desired application form.
- galenics carriers fillers, Zerfallbeein.ern, binders, lubricants, absorbents, diluents, previousskorrigentien, colorants, etc.
- the material of the present invention may be administered orally, mucosally (such as sublingually, buccally, rectally, nasally or vaginally), parenterally (such as subcutaneously, intramuscularly, by bolus injection, intraarterial, intravenous), transdermally, or locally (such as, for example, direct application on the skin or topical application to an exposed organ or wound).
- mucosally such as sublingually, buccally, rectally, nasally or vaginally
- parenterally such as subcutaneously, intramuscularly, by bolus injection, intraarterial, intravenous
- transdermally or locally (such as, for example, direct application on the skin or topical application to an exposed organ or wound).
- tablets, dragees, film-coated tablets, capsules, pills, powders, granules, lozenges, suspensions, emulsions or solutions are suitable for oral administration.
- tablets, dragees, capsules, etc. may be obtained by casting the silica sol material obtained in step d) into a tablet-like or capsule-like form for generating a monolith.
- the tablets and capsules can also be prepared by the above-described inventive material in the form of a powder by conventional methods.
- the material according to the invention or a precursor thereof can be prepared with known excipients, for example inert diluents such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc and / or agents for achieving a depot effect such as carboxylpolymethylene, carboxymethylcellulose, cellulose acetate phthalate or polyvinyl acetate are added. Tablets can also consist of several layers.
- inert diluents such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone
- disintegrants such as corn starch or alginic acid
- binders such as starch or gelatin
- lubricants such as magnesium stearate or talc and / or agents for achieving
- the capsules containing the subject matter of the invention can be prepared, for example, by mixing the materials according to the invention or a precursor thereof with an inert carrier such as lactose or sorbitol and encapsulating them in gelatine capsules.
- Coated tablets can accordingly be prepared by coating cores produced analogously to the tablets with agents customarily used in tablet coatings, for example polyvinylpyrrolidone or shellac, gum arabic, talc, titanium oxide or sugar.
- the dragee wrapper can also consist of several layers, wherein the auxiliaries mentioned above in the case of the tablets can be used.
- parenteral administration injection and infusion preparations are possible.
- crystal suspensions may be used for intraarticular injection.
- liquid formulations such as aqueous and oily injection solutions or suspensions and corresponding depot preparations can be used.
- the materials according to the invention can be used in the form of suppositories, capsules, solutions (for example in the form of enemas) and ointments both for the systemic and for the Local therapy can be used.
- solutions for example in the form of enemas
- ointments both for the systemic and for the Local therapy
- Liquid formulations such as injection solutions or suspensions can be obtained, for example, by adding the above-described material according to the invention in the form of a powder with suitable aqueous or oily solvents.
- Other types of preparation are known to the person skilled in the art.
- Solutions or suspensions of the material according to the invention may additionally contain taste-improving agents such as saccharin, cyclamate or sugar and, for example, flavorings such as vanillin or orange extract. They may also contain suspending aids such as sodium carboxymethylcellulose or preservatives such as p-hydroxybenzoates. Suitable suppositories can be prepared, for example, by mixing with suitable carriers such as neutral fats or polyethylene glycol or derivatives thereof. The solutions described can also be used, for example, for the treatment of dental plaque or gum disease (eg via an injection or for rinsing the oral cavity).
- taste-improving agents such as saccharin, cyclamate or sugar and, for example, flavorings such as vanillin or orange extract. They may also contain suspending aids such as sodium carboxymethylcellulose or preservatives such as p-hydroxybenzoates. Suitable suppositories can be prepared, for example, by mixing with suitable carriers such as neutral fats or polyethylene glycol or derivatives thereof. The solutions described
- Wound plasters are preferably made of fibers or a fiber matrix (fleece) of the materials according to the invention as described in the prior art.
- the material according to the invention or a precursor thereof can be produced by a coating method, for example by dipping an article or body to be coated in the silica sol material described above in step d), by casting or by spin-coating or spraying a be coated such silica sol material.
- the silica sol material is preferably applied to implants, autografts, vascular prostheses, dental prostheses or heart valves, and particularly preferably to autografts, dental prostheses and heart valves.
- the abovementioned forms of application may also contain other pharmaceutical active substances which can be added during the production process.
- FIG. 1 Neoangiogenesis with the addition of VEGF and material according to the invention
- Polyhydroxykieselkladreethylester- connection in the form of a fiber matrix to human endothelial cells (in vitro) detected via specific antibodies against the surface marker CD31.
- Control shows neo-angiogenesis of human endothelial cells without addition of VEGF or PKEE (negative control).
- K negative control.
- K negative control
- S / CD31 material according to the invention and detection of neoangiogenesis via CD31 antibodies
- S / vWF material according to the invention and detection of neoangiogenesis via vWF antibody
- V / CD31 VEGF and detection of neoangiogenesis via CD 31 antibody
- V / vWF VEGF and detection of neoangiogenesis via vWF antibody.
- * p ⁇ 0.05 vs control (Student t-test).
- the mixture obtained by this step was subsequently evaporated at temperatures of 62 ° C with the addition of a trailing stream and stirring (60 rpm) to a dynamic viscosity (shear rate 10 s-1 at 4 ° C) of 1 Pa ⁇ s.
- the sol resulting from the ripening was then spun into the fiber.
- the fibers were produced in a conventional spinning plant.
- the dope was filled into a pressure cylinder cooled to -15 ° C.
- the dope was pressed through the nozzles with pressure.
- the flowable, honey-like material fell by its own weight in a spin shaft located under the pressure cylinder with 2 m length.
- Temperature and humidity were controlled in the spinning shaft. The temperature was 25 ° C and the humidity at 19%.
- the fibers thus spun are exposed directly after spinning for a period of 35 minutes to the same climatic conditions as in the spinning tower (ie for example a humidity of 19%, a temperature of 25 ° C.) (conditioning of the spun fibers).
- a total of 8 different fiber webs of polyhydroxysilicic acid ethyl ester (type I to IV, AI, A2, Bl and B2) were prepared.
- the spun fibers have a diameter of about 50 ⁇ .
- the fiber webs AI, A2, B1 and B2 differ in terms of a different throughput in spinning (and thus the spinning time, see Table 1).
- the throughput indicated in g / h in Table 1 refers to the total sol flow rate.
- the pressure in the spinning container is adjusted so that the desired throughput is achieved.
- the fibrous webs Type I, Type II, Type III and Type IV differ in that, after the conditioning step described above and the packaging of the nonwovens, they are exposed to an environment with a relative humidity of 35% to 55% for storage for different periods until they are used During storage of the nonwovens in the packaging, the humidity in the packaging is greatly reduced by the presence of absorbents.
- Suitable packaging for the storage of fiber webs can be found for example in European Patent Application EP09007271.
- the compressibility was measured and calculated by thickness measurements (Precision Thickness Gauge Model 2000, Wolf Messtechnik GmbH) on the basis of the method steps described in the description.
- the ethoxy group content was measured by the standard Zeisel ether cleavage method.
- An internal standard solution was added to a fibrous matrix to be analyzed and, after addition of hydriodic acid, heated for one hour at 120 ° C. in a gas-tight glass vessel for one hour.
- Existing ethoxy groups are converted into ethyl iodide.
- the resulting ethyl iodide is determined by gas chromatography, the evaluation is carried out according to the method of the internal standard.
- the standard is toluene. 2.
- the inserts were supplemented with 350 .mu.l medium
- the inserts were supplemented with 350 .mu.l medium + 2 ng / ml VEGF and in the negative controls were the suspensions with 350 .mu.l medium + 20 ug / ml suramin, a potent VEGF- Inhibitor, filled up.
- the culture plates were cultured for 7-12 days, with full or partial replacement of the medium or medium contents every three days.
- vessel density refers to the area covered by newly formed capillary structures in the culture plate in relation to the total area
- the measurement of the vessel density is carried out by densitometric determination of the black pixel portions in a black-and-white image of the capillary structures colored by specific antibodies in comparison to that white surface of the plate background without capillary structures.
- percentage area of microvessels describes what percentage of the empty area (control corresponds to 100%) is taken up by neoangiogenesis-induced microvessels. The measurement of this parameter was done densitometrically. We examined black and white photos of the cultures for their percentage of black pixels ( ⁇ positive antibody staining of the endothelial cells). 3. In vivo experiments on neo-angiogenesis of the material according to the invention
- the polyhydroxy-silicic acid ethyl ester fiber matrices (A I, A 2, B 1 and B 2) according to the invention and the contours were transplanted and compared with each other.
- Each matrix was applied to 4 different wounds. 13 days after transplantation biopsies were taken from the wound area and immunohistochemistry was performed.
- Woundbrand Factor (vWF; Ulrich MM, et al., Wound Repair Rain, 2007 Jul-Aug., 1997) was described in relation to the blood vessels ; 15 (4): 482-90) stained with an antibody. The staining was evaluated by digital image analysis. The NIS-Ar software (Nikon) was used to quantify the results. Significantly increased staining (approximately 2.8 fold) of vWF regions from the material of the invention was observed as compared to the control (see Table 4).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Inorganic Chemistry (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- Psychiatry (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020127024620A KR20130036005A (ko) | 2010-02-24 | 2011-02-22 | 혈관신생유발 요법을 위한 실리콘을 함유하는 생분해성 물질 |
BR112012021355A BR112012021355A2 (pt) | 2010-02-24 | 2011-02-22 | "material contendo silício biologicamente degradável para a terapia pró-angiogenética. |
MX2012009717A MX2012009717A (es) | 2010-02-24 | 2011-02-22 | Material biodegradable que contiene silicio para terapia proangiogenica. |
US13/580,359 US20130115187A1 (en) | 2010-02-24 | 2011-02-22 | Biodegradable material containing silicon, for pro-angiogenetic therapy |
CA2790610A CA2790610C (en) | 2010-02-24 | 2011-02-22 | Biodegradable material containing silicon, for pro-angiogenetic therapy |
CN201180020550.4A CN102834101B (zh) | 2010-02-24 | 2011-02-22 | 用于促血管生成疗法的含硅的可生物降解的材料 |
AU2011219897A AU2011219897A1 (en) | 2010-02-24 | 2011-02-22 | Biodegradable material containing silicon, for pro-angiogenetic therapy |
RU2012140381/15A RU2573989C9 (ru) | 2010-02-24 | 2011-02-22 | Содержащий кремний биологически разлагаемый материал для проангиогенной терапии |
JP2012554316A JP5992341B2 (ja) | 2010-02-24 | 2011-02-22 | 血管新生促進療法用ケイ素含有生分解性材料 |
EP11706209A EP2538948A1 (de) | 2010-02-24 | 2011-02-22 | Siliciumhaltiges, biologisch degradierbares material zur pro-angiogenetischen therapie |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010008981A DE102010008981A1 (de) | 2010-02-24 | 2010-02-24 | Siliciumhaltiges, biologisch degradierbares Material zur pro-angiogenetischen Therapie |
DE102010008981.8 | 2010-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011104215A1 true WO2011104215A1 (de) | 2011-09-01 |
Family
ID=43759430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/052561 WO2011104215A1 (de) | 2010-02-24 | 2011-02-22 | Siliciumhaltiges, biologisch degradierbares material zur pro-angiogenetischen therapie |
Country Status (12)
Country | Link |
---|---|
US (1) | US20130115187A1 (de) |
EP (1) | EP2538948A1 (de) |
JP (1) | JP5992341B2 (de) |
KR (1) | KR20130036005A (de) |
CN (1) | CN102834101B (de) |
AU (1) | AU2011219897A1 (de) |
BR (1) | BR112012021355A2 (de) |
CA (1) | CA2790610C (de) |
DE (1) | DE102010008981A1 (de) |
MX (1) | MX2012009717A (de) |
RU (1) | RU2573989C9 (de) |
WO (1) | WO2011104215A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012131095A1 (en) * | 2011-03-31 | 2012-10-04 | Galderma Research & Development | Compositions comprising a filler product and at least one bioresorbable and biodegradable silica-based material |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1870649A1 (de) * | 2006-06-20 | 2007-12-26 | Octapharma AG | Gefriertocknung zum Erzielen einer bestimmte Restfeuchte durch beschränkte Desorptionsenergiepegeln. |
WO2017050976A1 (en) * | 2015-09-23 | 2017-03-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ephb2 polypeptides and uses thereof for the diagnosis and treatment of lupus |
US11759473B2 (en) * | 2018-02-16 | 2023-09-19 | American Nano, LLC | Topical compositions incorporating silica fibers |
US20190255223A1 (en) | 2018-02-16 | 2019-08-22 | American Nano, LLC | Silica fiber compositions and methods of use |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0621038A1 (de) * | 1993-03-19 | 1994-10-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Silikat-Polymer enthaltende pharmazeutische Zusammensetzungen |
DE19609551C1 (de) | 1996-03-12 | 1997-07-17 | Fraunhofer Ges Forschung | Biologisch degradierbare und/oder biologisch resorbierbare (Endlos)Fasern, Verfahren zu deren Herstellung und deren Verwendung als Verstärkungsfasern |
WO2001040556A1 (en) * | 1999-12-01 | 2001-06-07 | Bioxid Oy | Bioactive sol-gel derived silica fibers, methods for their preparation and their use |
WO2001042428A1 (de) | 1999-12-11 | 2001-06-14 | Axel Thierauf | Verfahren zur herstellung eines hautimplantats und nach dem verfahren hergestelltes implantat |
US6335457B1 (en) | 1999-10-15 | 2002-01-01 | Exsymol S.A.M. | Complex containing biologically assimilable orthosilicic acid, which is under solid form, stable and concentrated, and a process for preparation of said complex |
EP1262542A2 (de) | 2001-05-29 | 2002-12-04 | Axel Dr. Thierauf | Verfahren zur Herstellung von Zellen, Geweben und Organen |
US20030018011A1 (en) | 2000-02-18 | 2003-01-23 | Konishi Jin-Emon | Fatty acid-containing composition |
EP1391426A1 (de) * | 2002-08-12 | 2004-02-25 | Bio Minerals N.V. | Verfahren zur Herstellung eines kieselsäureenthaltenden Extrudates, das Extrudat, dessen Verwendung und eine das Extrudat enthaltende pharmazeutische Zusammensetzung |
WO2006069567A2 (de) | 2004-12-30 | 2006-07-06 | Bayer Innovation Gmbh | Verkürzte wundheilungsprozesse mittels neuartiger faservliese |
US20060178268A1 (en) | 2002-05-31 | 2006-08-10 | Sabalo N.V. | Aqueous solution of non-colloidal silicic acid and boric acid |
WO2008086970A1 (de) | 2007-01-15 | 2008-07-24 | Bayer Innovation Gmbh | Kieselsol-material zur herstellung von biologisch degradierbaren und/oder resorbierbaren kieselgel-materialien, dessen herstellung und verwendung |
WO2008148384A1 (de) | 2007-06-04 | 2008-12-11 | Axel Thierauf | Nicht-toxisches polyethoxysiloxan-material zur herstellung von biologisch resorbierbares und/oder bioaktives polyethoxysiloxan-material enthaltenden artikeln, dessen herstellung und verwendung |
WO2009018356A1 (en) | 2007-07-30 | 2009-02-05 | Medacure International, Inc. | Immune system modulator formulation |
WO2009052090A2 (en) | 2007-10-15 | 2009-04-23 | 7 Oaks Pharmaceutical Corporation | Silicate containing compositions and methods of treatment |
WO2010006708A1 (de) * | 2008-07-16 | 2010-01-21 | Bayer Innovation Gmbh | Kieselsol-material mit mindestens einem therapeutisch aktiven wirkstoff zur herstellung von biologisch degradierbaren und/oder resorbierbaren kieselgel-materialen für die humanmedizin und/oder medizintechnik |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0751354A (ja) * | 1993-08-20 | 1995-02-28 | Ube Ind Ltd | ポリエステル人工血管及びその製造方法 |
JPH0751356A (ja) * | 1993-08-20 | 1995-02-28 | Ube Ind Ltd | 抗血栓性医療用具及び抗血栓性付与方法 |
JP2005110708A (ja) * | 2003-10-02 | 2005-04-28 | Rikogaku Shinkokai | 骨修復材料、被覆骨修復材料、これらの製造方法 |
DE202006011668U1 (de) | 2006-07-29 | 2006-10-26 | Neo Energy Ag | Adaptiver Brennstoff |
DE102007061874A1 (de) | 2007-12-19 | 2009-06-25 | Bayer Innovation Gmbh | Nicht-toxisches Polysiloxan-Material zur Herstellung von biologisch resorbierbaren und/oder bioaktiven Polysiloxan-Material enthaltenden Artikeln, dessen Herstellung und Verwendung |
DE102010008982A1 (de) * | 2010-02-24 | 2011-08-25 | Bayer Innovation GmbH, 40225 | Siliciumhaltiges, biologisch degradierbares Material zur anti-inflammatorischen Therapie |
-
2010
- 2010-02-24 DE DE102010008981A patent/DE102010008981A1/de active Pending
-
2011
- 2011-02-22 JP JP2012554316A patent/JP5992341B2/ja active Active
- 2011-02-22 AU AU2011219897A patent/AU2011219897A1/en not_active Abandoned
- 2011-02-22 BR BR112012021355A patent/BR112012021355A2/pt not_active IP Right Cessation
- 2011-02-22 WO PCT/EP2011/052561 patent/WO2011104215A1/de active Application Filing
- 2011-02-22 RU RU2012140381/15A patent/RU2573989C9/ru active
- 2011-02-22 KR KR1020127024620A patent/KR20130036005A/ko not_active Application Discontinuation
- 2011-02-22 MX MX2012009717A patent/MX2012009717A/es not_active Application Discontinuation
- 2011-02-22 CA CA2790610A patent/CA2790610C/en active Active
- 2011-02-22 CN CN201180020550.4A patent/CN102834101B/zh active Active
- 2011-02-22 US US13/580,359 patent/US20130115187A1/en not_active Abandoned
- 2011-02-22 EP EP11706209A patent/EP2538948A1/de not_active Withdrawn
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0621038A1 (de) * | 1993-03-19 | 1994-10-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Silikat-Polymer enthaltende pharmazeutische Zusammensetzungen |
US5534509A (en) | 1993-03-19 | 1996-07-09 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition regulating function of a living body |
DE19609551C1 (de) | 1996-03-12 | 1997-07-17 | Fraunhofer Ges Forschung | Biologisch degradierbare und/oder biologisch resorbierbare (Endlos)Fasern, Verfahren zu deren Herstellung und deren Verwendung als Verstärkungsfasern |
US6335457B1 (en) | 1999-10-15 | 2002-01-01 | Exsymol S.A.M. | Complex containing biologically assimilable orthosilicic acid, which is under solid form, stable and concentrated, and a process for preparation of said complex |
WO2001040556A1 (en) * | 1999-12-01 | 2001-06-07 | Bioxid Oy | Bioactive sol-gel derived silica fibers, methods for their preparation and their use |
WO2001042428A1 (de) | 1999-12-11 | 2001-06-14 | Axel Thierauf | Verfahren zur herstellung eines hautimplantats und nach dem verfahren hergestelltes implantat |
US20030018011A1 (en) | 2000-02-18 | 2003-01-23 | Konishi Jin-Emon | Fatty acid-containing composition |
EP1262542A2 (de) | 2001-05-29 | 2002-12-04 | Axel Dr. Thierauf | Verfahren zur Herstellung von Zellen, Geweben und Organen |
US20060178268A1 (en) | 2002-05-31 | 2006-08-10 | Sabalo N.V. | Aqueous solution of non-colloidal silicic acid and boric acid |
US20060099276A1 (en) | 2002-08-12 | 2006-05-11 | Vanden Berghe Dirk A R | Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate |
EP1391426A1 (de) * | 2002-08-12 | 2004-02-25 | Bio Minerals N.V. | Verfahren zur Herstellung eines kieselsäureenthaltenden Extrudates, das Extrudat, dessen Verwendung und eine das Extrudat enthaltende pharmazeutische Zusammensetzung |
WO2006069567A2 (de) | 2004-12-30 | 2006-07-06 | Bayer Innovation Gmbh | Verkürzte wundheilungsprozesse mittels neuartiger faservliese |
DE102004063599A1 (de) | 2004-12-30 | 2006-07-13 | Bayer Innovation Gmbh | Verkürzte Wundheilungsprozesse mittels neuartiger Faservliese |
WO2008086970A1 (de) | 2007-01-15 | 2008-07-24 | Bayer Innovation Gmbh | Kieselsol-material zur herstellung von biologisch degradierbaren und/oder resorbierbaren kieselgel-materialien, dessen herstellung und verwendung |
WO2008148384A1 (de) | 2007-06-04 | 2008-12-11 | Axel Thierauf | Nicht-toxisches polyethoxysiloxan-material zur herstellung von biologisch resorbierbares und/oder bioaktives polyethoxysiloxan-material enthaltenden artikeln, dessen herstellung und verwendung |
WO2009018356A1 (en) | 2007-07-30 | 2009-02-05 | Medacure International, Inc. | Immune system modulator formulation |
WO2009052090A2 (en) | 2007-10-15 | 2009-04-23 | 7 Oaks Pharmaceutical Corporation | Silicate containing compositions and methods of treatment |
WO2010006708A1 (de) * | 2008-07-16 | 2010-01-21 | Bayer Innovation Gmbh | Kieselsol-material mit mindestens einem therapeutisch aktiven wirkstoff zur herstellung von biologisch degradierbaren und/oder resorbierbaren kieselgel-materialen für die humanmedizin und/oder medizintechnik |
Non-Patent Citations (4)
Title |
---|
"Remington's Pharmaceutical Science", 1980, MACK PUBLISHING COMPANY |
KANG YOUNG-MI ET AL: "Evaluations of osteogenic and osteoconductive properties of a non-woven silica gel fabric made by the electrospinning method.", ACTA BIOMATERIALIA JAN 2009 LNKD- PUBMED:18676190, vol. 5, no. 1, January 2009 (2009-01-01), pages 462 - 469, XP002630968, ISSN: 1878-7568 * |
MIDDELKOOP E ET AL.: "Porcine wound models for skin substitution and bum treatment", BIOMATERIALS, vol. 25, no. 9, April 2004 (2004-04-01), pages 1559 - 67, XP004481688, DOI: doi:10.1016/S0142-9612(03)00502-7 |
ULRICH MM ET AL.: "Expression profile ofproteins involved in scar formation in the healing process of full-thickness excisional wounds in the porcine model", WOUND REPAIR REGEN., vol. 15, no. 4, July 2007 (2007-07-01), pages 482 - 90 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012131095A1 (en) * | 2011-03-31 | 2012-10-04 | Galderma Research & Development | Compositions comprising a filler product and at least one bioresorbable and biodegradable silica-based material |
Also Published As
Publication number | Publication date |
---|---|
MX2012009717A (es) | 2013-02-11 |
RU2012140381A (ru) | 2014-03-27 |
CA2790610C (en) | 2018-02-13 |
EP2538948A1 (de) | 2013-01-02 |
DE102010008981A1 (de) | 2011-08-25 |
KR20130036005A (ko) | 2013-04-09 |
CN102834101A (zh) | 2012-12-19 |
CA2790610A1 (en) | 2011-09-01 |
CN102834101B (zh) | 2017-04-19 |
RU2573989C9 (ru) | 2016-07-27 |
RU2573989C2 (ru) | 2016-01-27 |
JP2013520463A (ja) | 2013-06-06 |
JP5992341B2 (ja) | 2016-09-14 |
BR112012021355A2 (pt) | 2016-10-25 |
US20130115187A1 (en) | 2013-05-09 |
AU2011219897A1 (en) | 2012-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2538949B1 (de) | Siliciumhaltiges, biologisch degradierbares material zur anti-inflammatorischen therapie | |
Mârza et al. | Skin wound regeneration with bioactive glass-gold nanoparticles ointment | |
Zhao et al. | Gadolinium phosphate/chitosan scaffolds promote new bone regeneration via Smad/Runx2 pathway | |
EP2303948B1 (de) | Verfahren zur herstellung eines kieselsol-materials mit mindestens einem therapeutisch aktiven wirkstoff zur herstellung von biologisch degradierbaren und/oder resorbierbaren kieselgel-materialen für die humanmedizin und/oder medizintechnik | |
Griffanti et al. | Bioinspired mineralization of a functionalized injectable dense collagen hydrogel through silk sericin incorporation | |
WO2011104215A1 (de) | Siliciumhaltiges, biologisch degradierbares material zur pro-angiogenetischen therapie | |
US20190262505A1 (en) | Regenerative medical material, preparation method therefor, and use thereof | |
EP3060268B1 (de) | Formstabile knochenersatzformkörper mit verbleibender hydraulischer aktivität | |
EP2152785B1 (de) | Nicht-toxisches polyethoxysiloxan-material zur herstellung von biologisch resorbierbares und/oder bioaktives polyethoxysiloxan-material enthaltenden artikeln, dessen herstellung und verwendung | |
Wu et al. | The osteogenesis of Ginsenoside Rb1 incorporated silk/micro-nano hydroxyapatite/sodium alginate composite scaffolds for calvarial defect | |
Zhan et al. | Polyphenol-mediated biomimetic mineralization of sacrificial metal-organic framework nanoparticles for wound healing | |
CN106139238A (zh) | 一种壳聚糖胶原海绵敷料及其制备方法 | |
Fan et al. | Cellulose acetate/Plerixafor wound dressings for transplantation of menstrual blood stem cells: Potential treatment modality for diabetic wounds | |
CN109529012A (zh) | 一种金属氧化物纳米白芨地龙蛋白复合物制备方法及应用 | |
EP3692191B1 (de) | Hochflexible degradierbare fasern | |
EP2958602B1 (de) | Zusammensetzung zur beschleunigten wundheilung geschädigten gewebes | |
TWI449544B (zh) | 硬組織修補複合材料及其製作方法 | |
Kohoolat et al. | A ternary composite hydrogel based on sodium alginate, carboxymethyl cellulose and copper-doped 58S bioactive glass promotes cutaneous wound healing in vitro and in vivo | |
US20240000994A1 (en) | Peptide nanogels for accelerated wound healing | |
Liu | Blow-spun Hybrid PCL-PEO/HNTs Scaffolds with Enhanced Biological and Mechanical Properties | |
Zhou et al. | Ao Zhou1, Sinan Chen2, Suresh Mickymaray3, Yaser E. Alqurashi3, Mathew Jeraud4, Biao Chen1* and Yunjiu Hu5 | |
Zhou et al. | Hydroxyapatite-collagen-carboxylic carbon quantum dot composite loaded with chrysin supported the proliferation and differentiation of human bone marrow derived mesenchymal stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180020550.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11706209 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2011706209 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011706209 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2790610 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/009717 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 221597 Country of ref document: IL Ref document number: 2012554316 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201004340 Country of ref document: TH Ref document number: 7377/DELNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011219897 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20127024620 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012140381 Country of ref document: RU Ref document number: A20121345 Country of ref document: BY |
|
ENP | Entry into the national phase |
Ref document number: 2011219897 Country of ref document: AU Date of ref document: 20110222 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13580359 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012021355 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012021355 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120824 |